Ghaziabad Online

Excessive Daytime Sleepiness (EDS) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Excessive Daytime Sleepiness (EDS) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

March 10
14:56 2021
Excessive Daytime Sleepiness (EDS) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Excessive Daytime Sleepiness (EDS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Excessive Daytime Sleepiness (EDS), historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness (EDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Excessive Daytime Sleepiness (EDS) is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period. Excessive Daytime Sleepiness (EDS) is often associated with a wide range of illnesses including metabolic, cardiovascular, neurological, psychiatric diseases but also with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. Excessive Daytime Sleepiness (EDS) is also commonly associated with social and economic consequences thus constituting a significant public health problem.

The diagnosis of Excessive Daytime Sleepiness (EDS) include questionnaires, identification of underlying medical condition, and diagnosis testing [i.e., Epworth Sleepiness Scale (ESS), Multiple Sleep Latency Test (MSLT), and Maintenance of Wakefulness Test (MWT)]. 

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

The Excessive Daytime Sleepiness (EDS) market report also covers emerging drugs, current treatment practices, Excessive Daytime Sleepiness (EDS) market share of the individual therapies, current and forecasted Excessive Daytime Sleepiness (EDS) Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Excessive Daytime Sleepiness (EDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

 Excessive Daytime Sleepiness (EDS) Market

Excessive Daytime Sleepiness (EDS) Market Key Facts

  • In 2017, the diagnosed prevalent population of Excessive Daytime Sleepiness (EDS) in the United States was 2,960,518. Among the 7MM, the highest cases of Excessive Daytime Sleepiness (EDS) were diagnosed in the US, in comparison to EU-5 and Japan.

  • Among the European countries, Germany had the highest diagnosed prevalent population of Excessive Daytime Sleepiness (EDS) with 590,827 cases, followed by France which had a diagnosed prevalent population of 487,146 in 2017. On the other hand, Italy had the lowest diagnosed prevalent population of 256,062 in 2017.

  • Of all the EU-5 countries, France ranked second for a diagnosed prevalent population of Excessive Daytime Sleepiness (EDS). In 2017, there were a total of 487,146 diagnosed prevalent cases of EDS, which includes 60,454 cases from Parkinson’s disease, 208,136 cases from OSA, 5,872 cases from Narcolepsy, 2,684 cases from IH, and 210,000 cases from Bipolar Disorder.

  • As per the DelveInsight analysis, it is observed that Japan has the second-highest diagnosed prevalent population of Excessive Daytime Sleepiness (EDS), among 7MM. As per DelveInsight’s estimates, Japan accounts for approximately 22.40% of the total diagnosed prevalent cases in the 7MM.

Key Benefits of Excessive Daytime Sleepiness (EDS) Market Report

  • Excessive Daytime Sleepiness (EDS) market report provides an in-depth analysis of Excessive Daytime Sleepiness (EDS) Market Size and Share, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Excessive Daytime Sleepiness (EDS) market report will help in developing business strategies by understanding the Excessive Daytime Sleepiness (EDS) Market trends & developments, key players, and future market competition that will shape and drive the Excessive Daytime Sleepiness (EDS) market in the upcoming years.

  • The Excessive Daytime Sleepiness (EDS) market report covers Excessive Daytime Sleepiness (EDS) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Excessive Daytime Sleepiness (EDS) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Excessive Daytime Sleepiness (EDS) Market

The Excessive Daytime Sleepiness (EDS) market size is expected to grow during the forecast period owing to the factors like an increase in the patient pool due to a rise in the prevalence of underlying medical conditions, and expected entry of emerging therapies.

The Excessive Daytime Sleepiness (EDS) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Excessive Daytime Sleepiness (EDS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Excessive Daytime Sleepiness (EDS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Excessive Daytime Sleepiness (EDS) Epidemiology

The Excessive Daytime Sleepiness (EDS) epidemiology section covers insights about the historical and current Excessive Daytime Sleepiness (EDS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Excessive Daytime Sleepiness (EDS) Drugs Uptake and Key Market Players

The Excessive Daytime Sleepiness (EDS) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness (EDS) market or expected to get launched in the market during the study period. The analysis covers Excessive Daytime Sleepiness (EDS) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Some of the key Excessive Daytime Sleepiness (EDS) companies involved in developing therapies for the treatment include:
BenevolentAI Bio
Avadel Pharmaceuticals
Theranexus
Jazz Pharmaceuticals
Axsome Therapeutics
Bioprojet Pharma
Harmony Biosciences
Suven Life Sciences
And many others.

Excessive Daytime Sleepiness (EDS) therapies covered in the report include:
BEN-2001
FT218
Xywav (JZP-258) (for EDS in IH)
AXS-12 (Reboxetine)
Wakix (Pitolisant) (for EDS in OSA)
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Excessive Daytime Sleepiness (EDS) Competitive Intelligence Analysis

4. Excessive Daytime Sleepiness (EDS) Market Overview at a Glance

5. Excessive Daytime Sleepiness (EDS) Disease Background and Overview

6. Excessive Daytime Sleepiness (EDS) Patient Journey

7. Excessive Daytime Sleepiness (EDS) Epidemiology and Patient Population

8. Excessive Daytime Sleepiness (EDS) Treatment Algorithm, Current Treatment, and Medical Practices

9. Excessive Daytime Sleepiness (EDS) Unmet Needs

10. Key Endpoints of Excessive Daytime Sleepiness (EDS) Treatment

11. Excessive Daytime Sleepiness (EDS) Marketed Products

12. Excessive Daytime Sleepiness (EDS) Emerging Therapies

13. Excessive Daytime Sleepiness (EDS) Seven Major Market Analysis

14. Attribute Analysis

15. Excessive Daytime Sleepiness (EDS) Market Outlook (7 major markets)

16. Excessive Daytime Sleepiness (EDS) Access and Reimbursement Overview

17. KOL Views on the Excessive Daytime Sleepiness (EDS) Market.

18. Excessive Daytime Sleepiness (EDS) Market Drivers

19. Excessive Daytime Sleepiness (EDS) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Related Reports
Excessive Daytime Sleepiness (EDS) Epidemiology Forecast
DelveInsight’s Excessive Daytime Sleepiness (EDS) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology in the 7MM.

 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share